DRUG BRIGHT MINDS BIOSCIENCES INC. IFRS
Pharmaceutical Preparations · Nasdaq · SEC CIK 1827401 · Reporting currency CAD · Fiscal year ends 09/30
Financial factors as of 2024-09-30 (FY2024), by fiscal year; growth vs the previous fiscal year
Growth
Margins
Returns
Leverage & solvency
Cash quality & payout
Factor history charts and full statement history on Pro 🔒
Financial statements
| Unit: CAD | FY2024*2024-09-30 | FY2023*2023-09-30 |
|---|---|---|
| Income statement | ||
| Revenue | — | — |
| R&D expense | 1.18M | 5.00M |
| SG&A expense | 264,009 | 278,809 |
| Income tax | 0 | 0 |
| Net income | -2.80M | -7.37M |
| EPS (basic) | -0.65 | -1.98 |
| EPS (diluted) | -0.65 | -1.98 |
| Weighted avg. shares (diluted) | 4.31M | 3.72M |
| Balance sheet | ||
| Cash & equivalents | 5.72M | 6.75M |
| Current assets | 5.99M | 6.81M |
| Total assets | 6.10M | 6.88M |
| Current liabilities | 528,683 | 280,856 |
| Total liabilities | 568,259 | 280,856 |
| Shareholders' equity | 5.54M | 6.60M |
| Cash flow statement | ||
| Operating cash flow | -1.85M | -7.02M |
| Financing cash flow | 810,572 | 2.19M |
| Depreciation & amortization | 73,357 | 72,450 |
| Stock-based compensation | 839,771 | 1.15M |
Free plan shows the latest 2 periods; Pro shows all 6 🔒
· This company reports under IFRS: some line items differ from US GAAP — operating income is not required, interest expense may be broader "finance costs", and banks have no standard revenue line.
· This company does not report gross profit in XBRL.
· Amounts are in the company's reporting currency, CAD, not USD; the site does no currency conversion.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.